EGFR and non-small cell lung carcinoma: However, recent studies have demonstrated that although at a small percentage (16–18), additional driver alterations coexist with EGFR mutations in TKI therapy-naïve NSCLC and may impact EGFR-TKI efficacy and partly explain the intrinsic resistance in some patients (19).